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   Retinitis pigmentosa (RP) is an inherited retinal disease that leads to degeneration 
of the retina through loss of rod and cone photoreceptor cells and subsequent loss of vision.  
RP affects approximately 1.5 million people world-wide.  Mutations causing autosomal 
dominant retinitis pigmentosa (adRP) have been identified in 23 different genes.  However, 
these mutations only account for approximately 70% of known adRP cases in Caucasians of 
Western-European origin and for an even smaller percentage of cases in other ethnicities.  
My research aims to increase the number of known genes associated with adRP by using an 
array of advanced genetic techniques to search for the disease-causing gene and mutation in 
a large African American family that has been clinically diagnosed with adRP.  Sanger 
sequencing, targeted-capture next-generation sequencing (NGS), and multiplex ligation-
dependent probe amplification (MLPA) were used to evaluate and eliminate the known 
adRP genes as the genetic cause of disease in this family.  Whole-genome linkage mapping 
followed by fine-point haplotype analysis mapped the disease locus to a 7.7 mega-base 
region on chromosome 19q.  Five candidate genes from within this disease locus were 
chosen based on their biological relevance to RP and analyzed for possible disease-causing 
mutations.  Whole-exome sequencing and whole-genome sequencing were used to identify 
63 rare variants located throughout the disease locus that segregate with disease in this 
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family.  Additional genetic and bioinformatic analyses were completed to evaluate these 
variants’ potential to be disease-causing.   
Despite being unable to single-out the disease-causing mutation from among the 
variants found to segregate with disease in this family, the wealth of data produced in this 
study will provide necessary genetic information that will continue to aid others in the 
search for this family’s disease-causing gene.  Once this novel adRP gene is identified, it 
will provide valuable insights that can be used in the diagnosis and prognosis of RP in this 
family and in other RP patients identified to have mutations in the same underlying gene.  
Of more importance, identification of the remaining disease-causing genes for adRP is 
necessary for the continued success that has been seen in the development of treatments and 
therapies for RP patients. 
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Chapter 1: Introduction 
Our sense of sight is considered by many to be the most valuable and most 
frequently used of our five senses.  Unfortunately, patients diagnosed with retinitis 
pigmentosa (RP) lose their vision, forcing them to adapt to this life-altering change as best 
as they are able.  The research contained in this study aims to help continue the success seen 
in identifying the genetic causes of RP and ultimately provide clinicians and scientists with 
the information they need to help diagnose and, one day, treat RP patients.   
Retinitis Pigmentosa Background 
RP is an inherited retinal degeneration that results in progressive loss of the rod 
photoreceptor cells. [1 - 3]  Photoreceptors are specialized sensory cells located in the outer 
nuclear layer of the retina that are responsible for absorption of light and turning light into 
signals that can be sent to the brain. [1, 3 - 4]  There are two types of photoreceptors, rods 
and cones. [4]  Rods are concentrated around the periphery of the retina and are responsible 
for monochromatic vision at night and in dim lighting. [1]  Cones are concentrated in the 
center of the retina and are responsible for color discrimination and high acuity vision. [1]   
RP affects approximately 1 in 4,000 individuals and causes patients to progressively 
lose their vision. [1 - 2]  As RP is a rod photoreceptor dominated disease, patients’ vision 
loss typically starts with loss of their night vision. [1 - 3]  Progression of the disease will 
then lead to constriction of their visual fields, resulting in ‘tunnel vision’. [1 - 3]  Since 
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degeneration of rod photoreceptor cells often results in secondary degeneration of cone 
photoreceptor cells, many patients will become completely blind as vision loss progresses 
into their central retina. [1 - 3]  Additional clinical symptoms include the presence of 
intraretinal pigmentation (typically referred to as ‘bone spicule’ pigmentation), retinal blood 
vessel attenuation, and waxy optic disc pallor seen in the fundus photographs of a patient’s 
retina (Figure 1). [1 - 3]  Electroretinograms (ERGs) of RP patients, which measure the 
electronic response of the retina to flashes of light, are seen as abnormal and diminished and 
often progress to completely nonrecordable. [1 - 2] 
RP is an extremely heterogeneous disease that displays multiple examples of clinical 
heterogeneity.  The age of onset, degree of severity, and level of cone involvement can vary 
from patient to patient, even within the same family. [1 - 3]  Some RP genes, such as 
PRPF31 and RP1, have exhibited cases of incomplete penetrance, and different mutations in 
the same gene may cause differing RP symptoms. [2, 5]  There are also syndromic forms of 
RP in which there are additional non-ocular symptoms associated with the disease.  For 
example, Usher syndrome, in which RP is associated with hearing loss, is the most common 
syndromic form of RP. [1 - 2]  Another major form of syndromic RP is Bardet Biedl 
syndrome, in which obesity, developmental delay, polydactyly, hypogenitalism, and renal 
disease are associated with RP to varying degrees. [1 - 2] 
RP also exhibits high levels of genetic heterogeneity.  RP has multiple forms of 
inheritance, including autosomal dominant, autosomal recessive, X-linked, and rare cases of 
digenic and mitochondrial inheritance. [1 - 2]  The autosomal dominant form accounts for 
approximately 30% of known non-syndromic RP cases in the US, while the autosomal 
recessive form accounts for approximately 20% of known cases. [6]  X-linked forms 
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Figure 1. Fundus photographs of a normal (left) and RP (right) retina.  The 
clinical features of RP, ‘bone spicule’ pigmentary deposits, retinal blood vessel 
attenuation, and waxy optic disc pallor, can be seen in the retina affected by RP.  
[Figure reprinted by permission from Macmillan Publishers Ltd: The EMBO 
Journal (Farrar, G.J., Kenna, P.F., Humphries, P. On the genetics of retinitis 
pigmentosa and on mutation-independent approaches to therapeutic intervention. 
EMBO J. 21, 857-864 (2002) ), copyright 2002.] 
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account for an additional 15% of known non-syndromic RP cases, and 5% of these 
nonsyndromic cases are early-onset forms of RP that are usually diagnosed as Lebers 
congenital amaurosis (LCA). [6]  Approximately 30% of remaining nonsyndromic RP cases 
are isolated or simplex cases. [6]  The majority of these isolated cases will likely be 
diagnosed with recessive RP mutations, but dominant-acting mutations and X-linked 
mutations are also included among these individuals. [6]  To date, 63 genes have been 
identified to cause non-syndromic RP.  Twenty-three genes have been identified to cause 
autosomal dominant RP (adRP), 42 genes to cause autosomal recessive RP (arRP), and three 
genes to cause X-linked RP (XLRP). [5, 7]  These numbers add up to more than 63 because 
many RP genes can cause more than one form of RP.  Approximately 3,100 different 
mutations have been reported in these genes. [5]  These genes encode proteins involved in a 
wide range of functions that include phototransduction, pre-mRNA splicing, retinal 
development, and photoreceptor outer-segment structure (Figure 2). [1, 4, 7] 
The family examined in this study was clinically diagnosed with adRP after the 
proband received a thorough visual function exam at the Retina Foundation of the Southwest 
in Dallas, Texas.  Therefore, the remainder of this dissertation will focus on the non-
syndromic, autosomal dominant form of RP. 
Previous Identification of adRP Genes 
In 1990, linkage analysis and candidate gene sequencing were used to identify the 
first adRP gene, rhodopsin (RHO). [9]  Since then, each of the remaining adRP genes (Table 
1) has also been identified with the traditional genetic methods of linkage analysis followed 
by candidate gene sequencing. [10 - 13]  RPE65, one of the 23 known adRP genes, 
represents the first successful use of next-generation sequencing (NGS) technologies in the  
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Figure 2. Pie chart of the genes involved in photoreceptor degeneration grouped 
into functional categories.  ECM, extracellular matrix; VRD, vitreoretinal 
degeneration.  [Figure reprinted by permission from Macmillan Publishers Ltd: 
Nature Reviews Genetics (Wright, A.F., Chakarova, C.F., Abd El-Aziz, M.M., 
Bhattacharya, S.S. Photoreceptor degeneration: genetic and mechanistic 
dissection of a complex trait. Nature Rev. Genet. 11, 273-284 (2010) ), copyright 
2010.] 
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Genea Protein Product Chromosome Mutationsb 
BEST1 Bestrophin 1 11 238 
CA4 Carbonic anhydrase 4 17 7 
CRX Cone-rod otx-like photoreceptor homeobox transcription factor 19 54 
FSCN2 Retinal fascin homolog 2, actin bundling protein 17 1 
GUCA1B Guanylate cyclase activating protein 1B 6 3 
IMPDH1 Inosine monophosphate dehydrogenase 1 7 15 
KLHL7 Kelch-like 7 protein 7 3 
NR2E3 Nuclear receptor subfamily 2 group E3 15 50 
NRL Neural retina lucine zipper 14 14 
PRPF3 Human homolog of yeast pre-mRNA splicing factor 3 1 3 
PRPF6 Human homolog of yeast pre-mRNA splicing factor 6 20 2 
PRPF8 Human homolog of yeast pre-mRNA splicing factor C8 17 21 
PRPF31 Human homolog of yeast pre-mRNA splicing factor 31 19 66 
PRPH2 Peripherin 2 6 123 
RDH12 Retinol dehydrogenase 12 14 67 
RHO Rhodopsin 3 162 
ROM1 Retinal outer segment membrane protein 1 11 11 
RP1 RP1 protein 8 68 
RP9 RP9 protein or PIM1-kinase associated protein 1 7 2 
RPE65 Retinal pigment epithelium-specific 65 kD protein 1 136 
SEMA4A Semaphorin 4A 1 3 
SNRNP200 Small nuclear ribonucleoprotein 200kDa (U5) 2 10 
TOPORS Topoisomerase I binding arginine/serine rich protein 9 9 
a
 Number of known adRP genes is based on the RetNet database, 
http://www.sph.uth.tmc.edu/retnet/ , accessed October 2013 [7] 
b Number of mutations in known adRP genes is based on the Human Gene Mutation 
Database, http://www.hgmd.cf.ac.uk/ , accessed November 2013 [8] 
 
Table 1. Autosomal dominant retinitis pigmentosa genes 
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identification of a dominant RP gene.  RPE65 had previously been identified to cause arRP 
and Leber congenital amaurosis (LCA). [14]  RPE65’s dominant acting mutation was 
identified by whole-exome sequencing and the simultaneous use of linkage analysis and 
candidate gene sequencing. [14]   
Despite the success seen in identifying the genetic causes of adRP over the past two 
decades, the 23 genes known to cause adRP only account for 65-70% of known cases of 
adRP. [5, 14 - 15]  While linkage analysis and candidate gene sequencing has contributed to 
the identification of all 23 adRP genes, it is a labor- and resource-intensive process.  These 
traditional genetic approaches have also had difficulty overcoming some aspects of rare 
genetic diseases such as high levels of genetic heterogeneity, incomplete penetrance, and the 
availability of only a small number of patients to study. [16]  Therefore, many hope that 
NGS is the powerful and unbiased technology that will help us solve the remaining 
genetically unknown adRP cases. 
Next-Generation Sequencing 
The advent of NGS technologies and the continual improvement of these 
technologies has exponentially reduced the cost and increased the speed of sequencing, 
thereby aiding geneticists in their search for the genetic causes of Mendelian diseases. [16 - 
18]  The challenge that still remains for the use of NGS strategies in the search for novel 
disease genes (especially in dominant diseases) is how to identify disease-causing mutations 
from among the wealth of genetic data produced by whole-exome and whole-genome 
sequencing. [16 - 18]  The large amount of variant data to search through, an inability to 
completely understand the effects of non-coding variation, the presence of non-pathogenic 
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polymorphisms, and sequencing errors adds complications to an already difficult process. 
[17 - 18] 
While NGS has led to the identification of one adRP gene, RPE65, it has been most 
successful in the identification of autosomal recessive disease-causing genes, aided by the 
ability to use homozygosity mapping in the identification process (5, 14, 19 - 20).  
Additionally, most successes in identification of the disease-causing gene in autosomal 
dominant disorders have been preceded by linkage analysis of a pedigree where 
identification of the disease locus helped to focus the search. [14, 16] 
My Research 
The goal of my research is to identify the disease-causing gene and mutation in a 
large African American family that has been clinically diagnosed with adRP.  A systematic 
use of multiple genetic technologies was employed in the search for this family’s disease-
causing gene (Figure 3).  Following enrollment and clinical characterization of the family 
analyzed in this study (Chapter 2), all previously known causes of adRP were evaluated and 
eliminated as their genetic cause of disease (Chapter 3).  Furthering the pursuit of their 
genetic cause of disease, whole-genome linkage analysis was performed to identify the 
disease locus (Chapter 4).  Five candidate genes based on biological relevance and previous 
adRP information found within this region were sequenced with the end goal of identifying 
potential disease-causing mutations (Chapter 5).  After analysis of these candidate genes 
failed to elucidate the disease-causing mutation, NGS technologies were used to continue 
the search and identify all genetic variation present within the chromosome 19q disease 
locus (Chapter 6).  Additional genetic and bioinformatic analyses were completed to assess 
the pathogenic potential of all variants segregating with disease in the family (Chapter 7). 
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Identifying the genetic cause of this African American family’s adRP will provide 
clinicians and scientists with valuable information, which can be used in a more thorough 
diagnosis and prognosis of their disease.  This information will also be used to benefit other 
RP patients with mutations in the same gene.  Finally, identification of the disease-causing 
gene and subsequent identification of the biological pathway involved in the disease will aid 
in the development of treatments for RP patients with mutations in this gene. 
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Figure 3. Flow chart of the analytical steps used in this study.  The steps are 
arranged in a circle to illustrate the cyclic nature of this research process; each 
new piece of information involves a re-evaluation of what we know at all of the 
previous steps and feeds in to how we approach the following steps. 
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Chapter 2: Family Acquisition and Clinical Characterization 
Introduction 
One limiting factor for studying rare genetic diseases is availability of genetic and 
phenotypic information from patients with the disease.  RP’s vast amount of clinical and 
genetic heterogeneity can translate into an equally large amount of possible genetic causes 
of disease.  Thorough clinical examinations that note the presence of additional non-ocular 
symptoms, degree of severity, level of rod versus cone involvement, and possible cases of 
incomplete penetrance will help determine which of the known RP genes is the cause of 
disease and will help guide the search for a novel RP gene.  The ultimate goal of my 
research is to identify valuable genetic information that will aide in the diagnosis, prognosis, 
and eventual treatment of patients with RP.  To obtain this goal, RP patients willing to 
participate in these genetic research studies must be identified, enrolled, and clinically 
characterized.   
A large African American family, referred to as RFS132, was clinically diagnosed 
with adRP and enrolled in this study.  Several members of the family were given 
comprehensive visual function exams, and DNA samples were obtained from each of the 28 
participating family member for use in all proceeding genetic analyses. 
Methods 
Enrollment 
After the proband of the RFS132 family received a clinical diagnosis of adRP for his 
declining vision, several RFS132 family members were enrolled in my study at the Retina 
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Foundation of the Southwest in Dallas, Texas.  Additional family members were enrolled in 
the study when a few members of the Daiger Laboratory made a trip to the family’s home.  
Informed consent was obtained from each participating individual or from parents/guardians 
for individuals under age 18.  Each individual was also given a unique laboratory identifier 
that was used on all DNA samples and in construction of the family’s pedigree.  This study 
was performed in accordance with the tenets of the Declaration of Helsinki and was 
approved by the Committee for the Protection of Human Subjects of the University of Texas 
Health Science Center at Houston. 
Visual Function Exams 
 Several members of the RFS132 family received comprehensive visual function 
examinations at the Retina Foundation by Dr. David Birch and the Retina Foundation’s 
genetic counselor, Dr. Dianna Wheaton.  These visual function exams included 
measurement of best-corrected visual acuity (BCA), full-field International Society for 
Clinical Electrophysiology of Vision (ISCEV) standard dark-adapted electroretinograms 
(ffERG), dark-adapted visual thresholds, and Humphrey visual fields (30-2; Spot size III 
protocol). [21]  Fundus photographs and optical coherence tomography imaging (OCT) of 
the patients’ retinas were also part of the examination. 
DNA Extraction 
Blood or saliva samples were obtained from each study participant in the RFS132 
family.  DNA was extracted from whole blood using either the QIAamp DNA Blood kit or 
Gentra Puregene blood kit (Qiagen, Hilden, Germany).  DNA was extracted from saliva 
using the Oragene Saliva Collection Kit (DNA Genotek, Ontario, Canada). 
13 
 
Results 
To date, 28 members of the RFS132 family have been enrolled and appropriately 
consented for participation in this research.  A pedigree for this family was built from 
information collected from the family at the time of enrollment (Figure 4).  The twenty-eight 
individuals make up three generations of the RFS132 family and include 13 affected family 
members, 12 unaffected, at-risk family members, and three unaffected spouses.  DNA 
samples, in the form of blood or saliva, were collected from each of these individuals for use 
in this study. 
 Several members of this family (denoted with a “*” in Figure 4) were given 
comprehensive visual function exams.  The proband, RFS132-5463, has been examined 
three times since 1998.  His most recent examination was in 2011 at age 56.  At his last 
examination, RFS132-5463 had a visual acuity of 20/80 OD and 20/40 OS.  ISCEV-standard 
ERG rod responses to single flashes of blue light were reduced in amplitude by 18%.  Cone 
responses to 30-Hz flicker were reduced in amplitude by 14% and were significantly 
delayed in b-wave implicit time.  His dark-adapted visual thresholds were elevated 1.5 log 
units, and his central visual fields, measured by Humphrey perimetry, showed a large central 
scotoma covering most of the central visual field.  These findings are consistent with a 
diagnosis of RP. 
The remaining affected individuals that received exams, while seen at different ages, 
had varying degrees of severity in their symptoms.  For example, RFS132-7473 was seen in 
2011 at age 35, which is 21 years younger than RFS132-5463 at his last exam.  The results 
of his visual function exam displayed a higher degree of severity in the progression of his 
vision loss than for RFS132-5463.  At his 2011 examination, RFS132-7473 had a measured  
14 
 
 
 
 
 
 
 
Figure 4. Pedigree of the RFS132 family.  Blackened symbols indicate family 
members that have been diagnosed with RP.  “?” indicates a family member with 
an unknown disease status.  “*” denotes the family members that received 
comprehensive visual function exams. 
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visual acuity of count fingers OD and 20/400 OS.  ISCEV-standard ERG rod responses to 
single flashes of blue light were non-detectable.  Cone responses to 30-Hz flicker were 
reduced in amplitude by 94% and significantly delayed in b-wave implicit time.  His dark-
adapted visual thresholds were elevated 3.7 log units.  Like RFS132-5463 and RFS132-
7473, each of the remaining affected individuals who received exams also showed ERG 
results with diminished or non-recordable rod responses and diminished cone responses.  
Each individual also exhibited elevated dark-adapted visual thresholds. 
Discussion 
Studies such as this one would not be possible without the cooperation and willing 
participation of RP patients.  The successful enrollment of 28 individuals spread across three 
generations of the RFS132 family provides the background for this study.  DNA samples 
collected from each individual will be used to complete all the proceeding genetic analyses. 
RFS132’s visual function examinations provide clinical information that can be used 
to help guide the search for their genetic cause of disease.  Those examined displayed 
varying degrees of severity in their symptoms, which is typical of RP.  Each family member 
that received a comprehensive exam displayed poor visual acuity and elevated dark-adapted 
thresholds.  The family’s ERG responses showed significant loss of the cone photoreceptors 
in addition to the loss of their rod photoreceptors.  Examination of the family’s pedigree 
showed no detectable instances of non-penetrance. 
Working with the family is an important and ongoing process.  Since RP has varying 
degrees of severity and ages on onset, known cases of incomplete penetrance, and related 
syndromic forms of disease, getting patients in for updated examinations is imperative to 
obtaining an accurate clinical and molecular diagnosis.  Churchill, et al. 2013 and Wang, et 
16 
 
al. 2013 are examples of studies where identification of the genetic cause of disease resulted 
in the need to reassess a family’s clinical diagnosis. [15, 22]  Additionally, several members 
of RFS132, such as RFS132-7473, have children that can be enrolled in this study.  Each 
child of an affected family member has a 50% chance of inheriting the RP gene.  Those 
children carrying the affected haplotype might also have novel recombinations that could 
help narrow the search for the disease-causing gene.  Therefore, our clinical collaborators at 
the Retina Foundation and I will continue to encourage members of the RFS132 family to 
obtain updated visual function exams and will continue working towards enrolling 
additional family members in this study throughout the duration of the study. 
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Chapter 3: Elimination of Known Causes of Disease 
Introduction 
Scientists have made great progress over the past two decades in identifying the 
genetic causes of adRP.  The 23 known adRP genes allow for the molecular diagnosis of 65-
70% of known cases of adRP. [5, 7]  The first step in identifying RFS132’s disease-causing 
gene is to search for possible disease-causing mutations among the known adRP genes. 
While Sanger sequencing has long been considered the gold-standard of sequencing 
technologies, NGS strategies have seen an enormous growth in popularity over recent years. 
[16 - 18]  Whole-exome and whole-genome sequencing strategies have made an impact in 
identification of novel disease-causing genes. [16 - 17]  A third NGS strategy, targeted-
capture NGS, provides scientists with an efficient and powerful option to screen patients for 
all known causes of their disease. [5, 16]  Several recent studies have reported the successful 
use of targeted capture NGS analysis for molecular diagnosis of RP patients. [22 - 23]  In 
addition to the impressive molecular diagnosis rates, these NGS strategies allow for 
expansion of analysis beyond just the known RP genes by adding additional candidate 
retinal disease genes to the targeted capture step.  [22 - 24]  In several instances, this has 
resulted in the identification of genes that can cause multiple forms of RP or genes that can 
cause multiple types of inherited retinal dystrophies. [22 - 24] 
Sanger sequencing, multiplex ligation-dependent probe amplification (MLPA), and 
targeted-capture NGS were used to search for potential disease-causing mutations in the 
known adRP genes in the RFS132 family.  Sanger sequencing was used to sequence the 
exons and exon/intron junctions of the known adRP genes.  MLPA was used to screen for 
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copy number variants (CNVs) and genomic rearrangements that might be missed by 
conventional sequencing techniques in a subset of the known adRP genes.  NGS targeted 
capture was used to analyze the exons and splice junctions of 163 known retinal disease 
genes. 
Methods 
Sanger Sequencing 
A minimum of one affected individual from RFS132 was selected and screened for 
mutations in the known adRP genes, including the complete coding regions of CRX, 
GUCA1B, IMPDH1, PRPF6, PRPF31, RDS, RDH12, RHO, RP1, RPE65, SEMA4A, 
SNRNP200, and TOPORS and mutational hotspots of PRPF3 and PRPF8.  AmpliTaq 
Gold® 360 Master Mix (Life Technologies, Grand Island, NY) and M13-tailed primers 
designed in Primer3 were used to amplify genomic DNA in a 12.5 µL reaction volume for 
35 cycles. [25 - 26]  The resulting PCR product was treated with ExoSAP-IT® (Affymetrix, 
Santa Clara, CA).  Purified PCR product was sequenced bidirectionally with M13 primers 
and BigDye v1.1 (Life Technologies).  Sequence reactions were purified with BigDye 
Xterminator® purification kit and run on a 3500 Genetic Analyzer (Life Technologies).  
Sequence analysis was then performed with SeqScape® v3.0 or Sequencing Analysis (Life 
Technologies). 
MLPA 
 MLPA was completed as previously described using probe pairs designed to span the 
coding regions of CRX, FSCN2, PRPF31, RDS, RHO, RPE65, and TOPORS and mutational 
hotspots of PRPF3 and RP1, reagents in either one of two kits (MLPA P115 Retina or EK1 
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kit; MRC-Holland, Amsterdam, The Netherlands), and the manufacturer’s DNA detection-
quantification protocol. [27 - 28] Probes were designed based on the recommendations of 
MRC-Holland using Raw-Probe software (MRC-Holland). 
 Probe cocktails were hybridized overnight with 25-50 ng of genomic DNA.  
Hybridized probes were ligated and then PCR amplified following the manufacturer’s 
protocol.  PCR product was diluted in deionized formamide (Life Technologies) containing 
GeneScan-500 LIZ size standards (Life Technologies) and run on a 3100-Avant Genetic 
Analyzer (Life Technologies).  Initial analysis of PCR products was completed with 
GeneMapper® software v3.7 (Life Technologies).  Tables of peak heights and peak areas 
were exported from GeneMapper® to a spreadsheet in Excel (Microsoft, Redmond, WA.)  
Dosage quotients (DQs) were calculated for each probe as detailed by Stern et al. 2004. [29]  
A DQ of 1.0 would indicate the presence of two alleles, and a DQ of 0.5 or 1.5 would 
indicate the possible presence of either a deletion or duplication of the target sequence, 
respectively. [29] 
Targeted Capture NGS Sequencing 
One affected individual from the RFS132 family was screened for mutations in 163 
retinal disease genes (Appendix A) with targeted capture NGS in collaboration with Dr. Rui 
Chen at the Human Genome Sequencing Center, Baylor College of Medicine, Houston, 
Texas. [22]  Illumina libraries were prepared according to previously described protocols. 
(Illumina Inc, San Diego, CA) [22, 30]  NimbleGen SeqCap EZ Hybridization and Wash 
Kits and manufacturer’s protocol were used for the retinal gene capture. (Roch Nimblegen 
Inc, Madison, WI)  DNA libraries were quantified and sequenced, after capture of the 
targeted retinal genes, on an Illumina HiSeq 2000 following the manufacturer’s protocols.  
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The 100 base-pair (bp) paired end reads produced by sequencing were analyzed according to 
previously described methods. (22, 30) 
Results 
At least one affected member of the RFS132 family was screened for mutations in 
the known adRP genes, including the complete coding regions of CRX, GUCA1B, IMPDH1, 
PRPF6, PRPF31, RDS, RDH12, RHO, RP1, RPE65, SEMA4A, SNRNP200, and TOPORS 
and mutational hotspots of PRPF3 and PRPF8, by di-deoxy Sanger sequencing.  
Sequencing of these genes included the known coding exons and 15 bps of intronic 
sequence at exon/intron junctions.  Variations from the reference sequence were further 
analyzed for the possibility of causing disease.  A variant’s presence among unaffected, 
ethnically matched controls, identification as a known polymorphism in online genetic 
databases such as the 1000 Genomes Browser (http://browser.1000genomes.org/index.html) 
and the NHLBI Exome Sequencing Project Exome Variant Server (NHLBI GO Exome 
Sequencing Project (ESP): https://esp.gs.washington.edu/drupal/), and/or failure to co-
segregate with disease among additional family members eliminated the variants likelihood 
to cause disease. [31 - 32]  Sanger sequencing analysis failed to reveal any disease-causing 
mutations among the known adRP genes in this family. 
One affected family member was also screened for CNVs and genomic 
rearrangements in a subset of the known adRP genes, including the coding regions of CRX, 
FSCN2, PRPF31, RDS, RHO, RPE65, and TOPORS and mutational hotspots of PRPF3 and 
RP1 using MLPA.  The probes used for MLPA were designed to overlap with the PCR 
primers used in Sanger sequencing analysis, so any failure to amplify would also be 
21 
 
detected.  MLPA analysis did not reveal any CNVs or genomic rearrangements among the 
genes analyzed. 
The retinal disease gene capture panel completed in collaboration with Dr. Rui Chen 
of Baylor College of Medicine’s Human Genome Sequencing Center was used to screen an 
affected member of RFS132 for mutations in 163 retinal disease genes, including 48 RP 
genes and 115 additional retinal disease genes.  The capture panel included 2,560 exons and 
splice junction, totaling 649,804 bps.  The mean read depth coverage was 77X with 92% of 
the targeted region reaching at least 10X coverage.  Only 49 of the 2,560 exons had a read 
depth of less than five and, thus, were not efficiently covered.  The design of the capture 
panel also failed to include 21 exons of EYS and 51 exons of USH2A.  The sequencing data 
was analyzed with an automatic variant calling, filtering, and annotation pipeline that has 
been previously described. [22, 30]  Common polymorphisms were filtered out from initial 
variant calls by comparison to genetic databases such as the 1000 Genomes Browser 
(http://browser.1000genomes.org/index.html), dbSNP 
(http://www.ncbi.nlm.nih.gov/projects/SNP/), and the NHLBI Exome Sequencing Project 
Exome Variant Server (NHLBI GO Exome Sequencing Project (ESP): 
https://esp.gs.washington.edu/drupal/ ) and an internal control database of 997 exomes. [31 - 
33]  The remaining rare variants were annotated and evaluated for possible pathogenicity by 
comparison to the Human Gene Mutation Database (HGMD) and in silico analysis using 
dbNSFP. [8, 34]  Targeted capture NGS failed to reveal any disease-causing mutations 
among these 163 retinal disease genes in this family. 
 
 
22 
 
Discussion 
Sanger sequencing was used to sequence the coding regions of the known adRP 
genes.  Large insertions, deletions, or genomic rearrangements were screened for in a subset 
of these adRP genes using MLPA.  Targeted-capture NGS was used to sequence the exons 
of 48 RP genes and 115 retinal disease genes.  Variations identified within any of these 
genes were further evaluated for their potential to be disease-causing.  Each method failed to 
identify a disease-causing mutation in any of the genes analyzed. 
While these sequencing methods did not identify any disease-causing mutations 
within the coding regions or splice junctions of the genes analyzed, it does not fully 
eliminate intronic or regulatory variants located in or around these genes as potential causes 
of disease.  However, the following chapters will discuss additional analyses that further 
confirm the elimination of the known adRP genes as the cause of disease in this family.  The 
linkage analysis discussed in chapter 4 eliminates all but CRX as a possible cause of disease.  
Chapter 5 covers extending the Sanger sequencing analysis of CRX beyond the exons and 
exon/intron junctions.  Chapters 7 and 8 examine the identification and elimination of all 
NGS variants located in known adRP genes, including the intronic and regulatory regions.  
The combination of results from all these analyses caused the need to expand the search for 
RFS132’s genetic cause of disease to novel adRP genes. 
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Chapter 4: Linkage Mapping of Disease Locus 
Introduction 
The human genome is comprised of over three billion base-pairs of DNA organized 
into approximately 21,000 protein-coding genes.  Therefore, the opportunity to narrow the 
search for a family’s disease-causing gene to a specific chromosomal region of the genome 
will greatly increase researchers’ success for molecular diagnosis.  In fact, every known 
adRP gene has first been localized by linkage mapping. [10 - 13]  After eliminating the 
known adRP genes as the disease-causing gene in RFS132, the next step in identifying this 
family’s genetic cause of disease was to map the disease-causing gene to a specific 
chromosomal region. 
Whole-genome linkage analysis was performed on a subset of the RFS132 family 
using genotyping data from an Affymetrix 6.0 SNP array to identify potential chromosomal 
regions segregating with disease.  Short tandem repeat (STR) markers were then genotyped 
in the whole family and used to generate haplotypes of each candidate chromosomal region 
identified by whole-genome linkage analysis.  These haplotypes were then used to confirm 
and refine the identified regions.  Recombinant individuals in the RFS132 pedigree were 
used to redefine the boundaries of the disease locus.  Additionally, CNV probes on the 
Affymetrix 6.0 SNP array were used to search for copy number variations in a subset of the 
RFS132 family   
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Methods 
SNP Genotyping 
DNAs from 17 members of RFS132 (11 affected and 6 unaffected individuals) were 
available for whole-genome linkage analysis. Genotyping was completed using the 
Affymetrix Genome-Wide Human SNP Array 6.0 by the John P. Hussman Insititute for 
Human Genomics, Center for Genome Technology in Miami, Florida in collaboration with 
Dr. Susan Blanton.  An ND-8000 spectrophotometer (Thermo Fischer Scientific, Waltham, 
MA) and agarose gel electrophoresis was used to evaluate the quantity and quality of DNA 
respectively.  Qualifying DNA was digested with NspI and StyI restriction enzymes (New 
England Biolabs, Ipswich, MA, USA) and ligated to adapters.  The DNA was then amplified 
using adapter-specific primers. After purification, PCR products were fragmented, labeled, 
and loaded on the SNP arrays. Hybridization was completed overnight in a GeneChip 
Hybridization Oven (Affymetrix). Arrays were washed and stained with streptavidin 
phycoerythrin (SAPE) on the Fluidics Station 450 (Affymetrix). Arrays were scanned on a 
GeneChip Scanner 3000 7G (Affymetrix). 
Whole-Genome Linkage Analysis 
Genotyping Console software (Affymetrix) was used to make SNP genotype calls 
and perform CNV analysis on raw Affymetrix Genome-Wide Human SNP 6.0 array data.  
PLINK v1.07 (http://pngu.mgh.harvard.edu/purcell/plink/) was used for quality control and 
assessment. [35]  A subset of the genotyped SNPs was chosen for linkage analysis based on 
heterozygosity and inter-SNP distance.  The chosen SNPs were at least 0.2 cM apart and had 
an average heterozygosity of 0.5.  YRI (Yoruba in Ibadan, Nigeria) dataset allele 
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frequencies were used for this family’s calculations. [36]  Multipoint linkage analysis was 
performed using Merlin v1.1.2 (http://www.sph.umich.edu/csg/abecasis/Merlin/download/) 
and a dominant model with 90% penetrance in heterozygotes and a disease allele frequency 
of 0.0001. [37 - 38] 
STR Genotyping 
Polymorphic STR markers were selected for use from the UCSC Genome Browser 
(http://genome.ucsc.edu/) and were purchased from Life Technologies.  AmpliTaq Gold® 
360 Master Mix (Life Technologies) and fluorescently labeled primers (Life Technologies) 
were used to amplify patient DNA in a 7.5 µL reaction volume for 30 cycles.  Resulting 
PCR products were run on a 3500 Genetic Analyzer (Life Technologies). 
Manual Haplotype Analysis 
Raw STR genotype data were analyzed using GeneMapper® v5.0 (Life 
Technologies).  Individual haplotypes of each family member were generated by hand using 
the genotyped STR data and assembled onto the RFS132 pedigree. 
Results 
Affymetrix 6.0 genotypes were used to complete whole-genome, multipoint linkage 
analysis and CNV analysis on a portion of the RFS132 family.  CNV analysis of the data 
generated by the 946,000 copy number probes on the Affymetrix 6.0 SNP array in 
Genotyping Console software did not identify any copy number variants in RFS132.  
However, whole-genome linkage analysis using a subset of the SNP genotypes identified 
three chromosomal regions with a positive LOD score.  These linkage regions were located 
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on chromosomes 9, 18, and 19 with maximum multipoint LOD scores of 2.5, 3.5, and 3.8 
respectively (Figure 5).  The chromosome 9 linkage region was approximately 3.7 mega-
bases (Mb) in size and was flanked by rs1013217 and rs7852051.  The chromosome 18 
linkage region was approximately 5.3 Mb in size and was flanked by rs2879526 and 
rs4940674.  The final linkage region, on chromosome 19, was approximately 7.7 Mb in size 
and was flanked by rs2599472 and rs10405562.  The LOD scores on each of these specific 
chromosomal regions suggested they could be linked to the family’s disease. 
Fine-point haplotyping using STR markers flanking and spanning the three 
chromosomal regions identified by whole genome linkage analysis was completed on the 
original 17 samples plus at least 8 additional samples from RFS132 to confirm and refine the 
number of potential disease loci.  Nine STR markers (Table 2) were run on chromosome 9, 
and haplotypes were generated to search for one tracking with disease (Figure 6).  RFS132-
7827 and RFS132-5722 lacked the haplotype seen in the remaining affected family 
members.  Ten STR markers (Table 2) were run on chromosome 18, and haplotypes were 
generated to search for one tracking with disease on this chromosome (Figure 7).  Once 
again, RFS132-7827 and RFS132-5722 lacked the haplotype seen in the remaining affected 
family members.  Fifteen STR markers (Table 2; Appendix B) were run on chromosome 19, 
and haplotypes were generated to search for one tracking with disease (Figure 8).  One 
haplotype was found in each affected member of the RFS132 family, segregating 
appropriately with disease.  The affected haplotype was also seen in five unaffected, at-risk 
family members.  Further examination of the affected haplotype revealed multiple  
recombinant individuals.  A recombination between D19S420 and D19S900 in RFS132-
5721 redefined the centromeric boundary of the linkage region, and a recombination 
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Figure 5. Whole-genome linkage analysis results for chromosomes 9, 18, and 19 
(respectively). 
Chromosome 9 
Chromosome 18 
Chromosome 19 
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Chromosome 9 Chromosome 18 Chromosome 19 
D9S169 D18S1156 D19S220 
D9S52 D18S487 D19S420 
D9S911 D18S1119 D19S900 
D9S1878 D18S364 D19S538 
D9S1817 D18S1127 D19S903 
D9S1805 D18S69 D19S918 
D9S1859 D18S39 D19S908 
D9S1874 D18S1152 D19S219 
D9S2148 D18S1144 DM 
 D18S1103 D19S412 
  D19S606 
  D19S902 
  D19S904 
  D19S907 
  D19S553 
 
 
 
 
 
 
Table 2. STR markers. A list of the genetic markers used in 
the fine point haplotype analysis of the three linkage regions 
identified by whole-genome linkage analysis. 
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Figure 6. Results of manual haplotype analysis on chromosome 9.  The blue bars 
highlight the haplotype that best segregates with disease in the family on this 
chromosome.  RFS132-7827 and RFS132-5722 lack any portion of the affected 
haplotype. (Highlighted by red arrows) 
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Figure 7. Results of manual haplotype analysis on chromosome 18.  The green 
bars highlight the haplotype that best segregates with disease in the family on 
this chromosome.  RFS132-7827 and RFS132-5722 lack any portion of the 
affected haplotype. (Highlighted by red arrows) 
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Figure 8. Results of manual haplotype analysis on chromosome 19.  The purple 
bars highlight the haplotype segregating with disease in the family. 
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between D19S907 and D19S553 in RFS132-5722 redefined the telomeric boundary of the 
linkage region.  The resulting linkage region was still approximately 7.7 Mb in size.   
Discussion 
Data generated by the Affymetrix SNP array was used in whole-genome linkage 
analysis and CNV analysis.  CNV analysis did not identify any copy number variants.  
Whole-genome linkage analysis identified three linkage regions on chromosome 9, 18, and 
19 that warranted additional follow-up based on their maximum multipoint LOD scores of 
2.5, 3.5, and 3.8 respectively. 
STR markers often have a larger number of differing alleles than SNPs, making them 
more polymorphic.  The use of these highly polymorphic markers combined with the use of 
an extended pedigree provides the fine-point haplotype analysis step with the opportunity to 
confirm and refine the linkage regions identified with whole-genome linkage analysis on 
SNP data.  Examination of the haplotypes generated for chromosomes 9 and 18 showed that 
the most prominent haplotype did not appear in each affected family member.  Failure of a 
haplotype to co-segregate with disease in the family means these two linkage regions cannot 
be the disease locus.  The most prominent haplotype on chromosome 19 appeared in each 
affected family member.  Therefore, chromosome 19’s linkage region was confirmed as the 
most likely disease locus.  Recombination events in RFS132-5721 and RFS132-5722 
defined the centromeric and telomeric boundaries of this disease region.  There are multiple 
possible explanations for the presence of the affected haplotype in unaffected, at-risk 
RFS132 family members.  Some of these family members might not have started to show 
symptoms of RP, especially the youngest generation, since RP has a well-known varying 
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age of onset. [1 - 2]  Some of these family members may also never show symptoms of RP 
as in PRPF31 and RP1’s known cases of incomplete penetrance. [2] 
Overall, linkage analysis in RFS132 identified a 7.7 Mb disease region on 
chromosome 19q.  There are a large number of genes located throughout a region of this 
size, and several of these genes are promising candidates for RFS132’s cause of disease. 
 
 
 
 
 
 
 
 
 
 
 
34 
 
Chapter 5: Candidate Gene Sequencing 
Introduction 
Candidate gene sequencing has played a part in the identification of every known 
adRP gene to date.  The process allows scientists to incorporate data from multiple sources 
to knowledgably select and screen genes that are likely to cause disease based on their 
biological relevance to the disease.   For example, SNRNP200 was selected as a candidate 
gene for the RP33 locus by Zhao et al. 2009. [12]  SNRNP200 encodes a U5 small nuclear 
ribonucleoprotein (snRNP) 200 kDa helicase involved in the U4/U6 small nuclear RNA 
(snRNA) unwinding within the spliceosomal complex. [12]  Therefore, SNRNP200’s 
functional similarity as a member of the RNA splicing factor protein family to previously 
identified adRP genes, such as PRPF8, PRPF3, and PRPF31, made it a strong candidate for 
their study. [12]  Subsequent sequencing analysis of SNRNP200 resulted in the identification 
of adRP disease-causing mutations within the gene. [12] 
The next step in my study was to thoroughly characterize the disease region on 
chromosome 19q that was identified by linkage analysis of RFS132.  Multiple publically 
available databases were used to identify the number and nature of the genes located in the 
disease region.  This information and an extensive literature search were used to help make a 
well-informed selection of five candidate genes located within the disease region. 
 CRX, OPA3, CAPB5, SNRNP70, and SNRPD2, were selected for further analysis 
based on their biological relevance to RP.  The cone-rod otx-like homeobox (CRX) gene was 
selected as a candidate gene based on the previous identification of mutations causing RP, 
LCA, and cone-rod dystrophy within the gene. [7, 39]  The optic atrophy three (OPA3) gene 
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was the second candidate gene selected because it is also a known retinal disease gene with 
mutations that result in dominant optic atrophy. [7]  Calcium binding protein five’s (CABP5) 
retinal specific expression was the primary reason for its selection as the third candidate 
gene. [40]  Small nuclear ribonucleoprotein 70 kDa (U1) (SNRNP70) and small nuclear 
ribonucleoprotein D2 16.5kDa (SNRPD2) are each involved in pre-messenger RNA (pre-
mRNA) splicing and were selected as candidate genes for their functional similarity to 
known adRP genes such as PRPF3, PRPF8, and SNRNP200. [41 - 42]  Sanger sequencing 
was used to screen each of these candidate genes for mutations in members of the RFS132 
family.  Any identified variations were further genetically evaluated for their potential to be 
disease-causing. 
Methods 
Characterization of Linkage Region 
Several online genetic databases were used to characterize the chromosome 19q 
linkage region.  The UCSC Genome Browser (http://www.genome.ucsc.edu/index.html) was 
used to identify the total number and location of genes within the linkage region. [43]  The 
Ocular Genomics Institute’s (Harvard Medical School, Boston, MA) Human Retinal 
Transcriptome data (http://oculargenomics.meei.harvard.edu/index.php/ret-trans/110-
human-retinal-transcriptome) was used to evaluate the retinal expression of the genes 
located in the linkage region and locate any novel, retinal specific genes and splicing events. 
[44]  Several databases, including the 1000 Genomes Browser 
(http://browser.1000genomes.org/index.html), dbSNP 
(http://www.ncbi.nlm.nih.gov/projects/SNP/), and the NHLBI Exome Sequencing Project 
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Exome Variant Server (NHLBI GO Exome Sequencing Project (ESP): 
https://esp.gs.washington.edu/drupal/), were used to help evaluate the frequency and 
disease-causing potential of genetic variants identified within the linkage region. [31 - 33]  
Data from the ENCODE project, available as tracks within the UCSC Genome Browser, was 
used to help select candidate genes and evaluate the disease-causing potential of variants 
located in the intronic and regulatory regions of the linkage region. [45] 
Selection of Candidate Genes 
Five candidate genes, CRX, OPA3, CABP5, SNRNP70, and SNRPD2, were selected 
for further analysis on the basis of one or more criteria (Table 3).  These criteria include: 
known adRP disease-causing genes, associated with another type of retinal disease, high 
levels of retinal expression, and/or functional similarity to known adRP disease-causing 
genes. 
Sequencing 
At least two affected and one unaffected member of RFS132 were selected and 
screened for mutations in 5 candidate genes, including the complete coding regions of CRX, 
OPA3, CABP5, SNRNP70, and SNRPD2 along with the promoter region and 5' and 3' 
untranslated regions (UTRs) of CRX.  AmpliTaq Gold® 360 Master Mix (Life 
Technologies) and M13-tailed primers designed in Primer3 were used to amplify genomic 
DNA in a 12.5 µL reaction volume for 35 cycles. [25 - 26]  The resulting PCR products 
were treated with ExoSAP-IT® (Affymetrix).  Purified PCR products were sequenced 
bidirectionally with M13 primers and BigDye v1.1 (Life Technologies).  Sequence reactions 
were purified with BigDye Xterminator® purification kit and run on a 3500 Genetic  
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Gene Protein Product Reason For Selection 
CRX Cone-rod otx-like photoreceptor homeobox transcription factor Known adRP gene 
CABP5 Calcium binding protein 5 Retina specific expression 
OPA3 Optic atrophy 3 protein Known retinal disease gene 
SNRNP70 U1 small nuclear ribonucleoprotein 70 kDa 
Similar function to known adRP 
genes 
SNRPD2 Small nuclear ribonucleoprotein D2 16.5 kDa 
Similar function to known adRP 
genes 
 
 
 
 
 
 
 
 
Table 3: Candidate genes located in chromosome 19 linkage region 
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Analyzer (Life Technologies).  Sequence analysis was then performed with SeqScape® v3.0 
(Life Technologies). 
Results 
Characterization of RFS132’s disease region involved revealing the number of genes 
located in the region and identifying the exact location, presence of alternate transcripts, 
expression, and relation/interaction with other genes of each gene in the region.  The UCSC 
Genome Browser hg19/February 2009 build places 356 genes in the 7.7 Mb linkage region 
on chromosome 19q.  Many of the genes located in this gene-rich region are part of large 
gene families, and several databases show the presence of alternative transcripts for most of 
the genes located in this region.  Human retinal transcriptome data from Harvard’s Ocular 
Genomics Institute shows that 267 of the 356 genes in the linkage region are expressed in 
the retina.  A subsequent literature search helped with the prioritization and selection of 
candidate genes.  Five genes located within the chromosome 19q linkage region were 
selected for further analysis (Table 3). 
CRX, a known adRP gene cloned by Freund et al. in 1997, was selected as the first 
candidate gene. [7, 46]  CRX encodes a photoreceptor-specific transcription factor that is 
necessary for the differentiation and maintenance of normal rod and cone photoreceptors. [7, 
47]  Therefore, mutations in this gene result in photoreceptor degeneration and have been 
shown to cause RP, LCA, and cone-rod dystrophy. [7, 39]  Fifty-four different mutations 
have been identified within CRX, and the previous Sanger sequencing, MLPA, and targeted-
capture NGS analysis of CRX (discussed in chapter 2) have eliminated the possibility of 
these mutations causing disease in RFS132.  However, CRX’s distinction as the only 
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remaining adRP gene located within the disease locus warrants a confirmation of these 
results and expansion of the sequencing analysis completed on CRX. 
OPA3, a known retinal disease gene, was selected as the second candidate gene for 
analysis.  OPA3 encodes a protein in the mitochondrial inner membrane. [7, 48]  Mutations 
in this gene cause autosomal dominant optic atrophy and cataract (ADOAC) and type III 3-
methylglutaconic aciduria (MGA) with clinical symptoms that include early-onset bilateral 
optic atrophy, urinary excretion of 3-methylglutaconic acid and 3-methylglutaric acid, later-
onset spasticity, extrapyramidal abnormalities, ataxia, and cognitive deficit. [7, 48 - 49] 
CABP5 is part of a subfamily of calcium binding proteins. [40]  CABP5’s retinal 
specific expression was the main reason for its selection as a candidate gene. [40]  A 
literature search identified functional studies highlighting CABP5’s possible involvement in 
the visual process which strengthened its selection as a candidate gene.  Mice lacking 
CABP5 exhibit reduced sensitivity in the rod-mediated light responses of their retinal 
ganglion cells. [50]  These results suggest a role for CABP5 in the transmission of light 
through the retina. [50]   
SNRNP70 encodes the U1-70kDA snRNP, which is an essential component of the 
splicesomal complex.  During splicing of pre-mRNA, the U1 snRNP is responsible for 
recognizing the 5' splice site. [41]  SNRPD2 belongs to a small nuclear ribonucleoprotein 
family of proteins that assembles on a conserved sequence in the U1, U2, U4, and U5 
snRNAs to help form the core splicesomal complex. [42]  Functional similarity to known 
disease-causing genes is a common criterion for selection of candidate genes.  Therefore, 
SNRNP70 and SNRPD2’s participation in the splicing process is the basis of their selection 
as candidate genes. 
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At least two affected members and one unaffected member of the RFS132 family 
were screened for mutations in CRX, OPA3, CABP5, SNRNP70, and SNRPD2 using Sanger 
sequencing.  Sequencing of these genes included the known coding exons and 15 bps of 
intronic sequence at exon/intron junctions.  Since CRX is the only known adRP gene located 
in the chromosome 19q linkage region, it underwent more extensive screening.  For CRX, 
500 bps of the 5' promoter region, the 5' and 3' UTRs, and 50 to 100 bps of intronic 
sequence at the exon/intron junctions were sequenced.  A literature search of CRX also 
highlighted additional exons that were subsequently sequenced. [39, 44]  Variations from 
the reference sequence were further analyzed for the possibility of causing disease.  A 
variant’s presence among unaffected, ethnically matched controls, identification as a known 
polymorphism in online genetic databases such as the 1000 Genomes Browser 
(http://browser.1000genomes.org/index.html) and the NHLBI Exome Sequencing Project 
Exome Variant Server (NHLBI GO Exome Sequencing Project (ESP): 
https://esp.gs.washington.edu/drupal/), and/or failure to co-segregate with disease among 
additional family members eliminated the variants likelihood to cause disease. [31 - 33]  
Sanger sequencing analysis did not reveal any disease-causing mutations among the five 
candidate genes analyzed in this family. 
Discussion 
Genetic databases and information obtained from a literature search were used to 
characterize the disease locus on chromosome 19q.  Characterizing this region was an 
important step towards being able to identify genes with a possible connection to RP.  
Identification of these biological connections to RP provides a method for narrowing down 
the search for the disease-causing gene from among the 267 retinal expressed genes located 
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in RFS132’s disease locus.  Sanger sequencing the coding region of each retinal expressed 
gene would be an expensive and extremely labor-intensive task that few genetic labs could 
undertake.  Therefore, focus must be given to the ‘candidates’ deemed most likely to cause 
RP. 
Di-deoxy capillary electrophoresis sequencing was used to search for the presence of 
genetic alterations in CRX, OPA3, CABP5, SNRNP70, and SNRPD2.  Any deviations from 
the reference sequence of these genes were found to be common, known polymorphisms or 
failed to co-segregate with disease in the family.  Thus, no disease-causing mutations were 
found in the genes selected as likely candidates to cause RP. 
Although Sanger sequencing of these candidate genes did not uncover any disease-
causing mutations, this does not fully eliminate these genes as the genetic cause of disease in 
RFS132.  Genetic variants in the intronic and regulatory regions of these genes that have not 
yet been seen may be the underlying cause of this family’s RP.  This possibility is addressed 
in chapter 6 where my use of whole-exome and whole-genome sequencing to search for 
genetic variants in both the coding and non-coding regions of each gene in the chromosome 
19q linkage region is discussed.  New developments and improvements in sequencing 
technologies during the course of this long term project have helped shape the methodology 
used for our continued search of RFS132’s disease-causing mutation. 
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Chapter 6: Next-Generation Sequencing 
Introduction 
After using Sanger sequencing to search for RFS132’s disease-causing mutation in 
five candidate genes located in the disease locus, NGS technologies were employed to 
continue the search.  The use of multiple genetic technologies in this study represents the 
improvements seen in sequencing technologies during the evolution of this long-term project 
and allows us to make use of the benefits that each provides.  Sequencing each of the 356 
genes located in RFS132’s disease locus is a task that would have once been considered too 
costly and too time-consuming to undertake.  While candidate gene sequencing allows us to 
quickly narrow-in on the genes considered most likely to cause disease, NGS strategies have 
provided the opportunity to sequence each gene within the defined disease locus.  In fact, the 
advantages that NGS technologies provide over more conventional sequencing methods is 
turning it into the most popular method of disease-gene identification. [17 – 18]   
Why is NGS so popular? NGS has exhibited an impressive molecular diagnosis rate 
over the past few years.  Currently, the discovery of over 180 novel disease-causing genes 
can be attributed to the use of NGS. [16]  The massively parallel methods of NGS make it 
much faster than conventional sequencing methods.  NGS is also much less expensive per 
sequence than conventional sequencing methods.  NGS allows for direct identification of the 
disease-causing mutation while methods such as whole-genome linkage analysis and 
genome-wide association studies typically lack the power to identify specific causal 
variants. Finally, NGS does not involve the inclusion of any prior knowledge or assumptions 
about possible causes of disease like candidate gene sequencing, which might add bias to the 
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search for novel disease-causing mutations.  Despite all of these advantages, extensive 
follow-up analysis is required to identify the disease-causing mutation from among the large 
volume of sequencing data produced by NGS. 
Whole-exome sequencing was completed on eight members of the RFS132 family 
and was used to identify any genetic variation present throughout the coding and splice 
regions of their genomes.  This was followed by whole-genome sequencing of two members 
of the RFS132 family.  Whole-genome sequencing was completed to search for genetic 
variants among the non-coding regions of their genomes and to add read depth to the regions 
already assayed by whole-exome sequencing.  A set of discrete filters was then applied to 
the large number of genetic variants identified by these NGS strategies to remove the 
variants that could not be the cause of disease in this family. 
Methods 
Whole-Exome Sequencing 
Library Preparation 
Illumina paired-end libraries were made from 1 µg of DNA according to 
manufacturer's protocol with the following modifications: 1) DNA was fragmented into 
sizes ranging from 100–500 bp, using a Covaris S2 DNA Sonicator (Covaris Inc., Woburn, 
MA) 2) Illumina adapter-ligated DNA was amplified in a single 50 µl PCR reaction for five 
cycles, and 3) solid phase reversible immobilization (SPRI) bead cleanup was used to purify 
the PCR amplification and select for fragments 300–500 bp in size. 
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Exome Capture 
Sequencing libraries were hybridized with either a customized Agilent SureSelect 
All Exome Kit v2.0 (Agilent Technologies, Santa Clara, CA) or the Nimblegen SeqCap EZ 
Human Exome Library v2.0 (Table 4), according to the manufacturer's protocol. The KAPA 
SYBR FAST qPCR Kit (KAPA Biosystems, Woburn, MA) was used for library 
quantification.  Libraries were quantified using PicoGreen prior to paired-end sequencing 
(2x100 bp) on Illumina GAIIx or HiSeq2000 instruments. 
Sequence Alignment and Variant Calling 
Illumina reads passing instrument QC were aligned to the GRCh37-lite reference 
sequence with Burrows-Wheeler Aligner (BWA) v0.5.9 (http://bio-bwa.sourceforge.net/). 
[51]  Parameters –t 4 –q 5 (where t is the number of threads and q is the parameter for read 
trimming) were passed to the bwa aln command, and default parameters were used for other 
commands. [51]  Duplicates were marked by Picard v1.46 
(http://picard.sourceforge.net/index.shtml).  Putative single-nucleotide variants (SNVs) were 
called using VarScan v2.2.9 (http://varscan.sourceforge.net/index.shtml) with parameters --
min-coverage 3 --min-var-freq 0.20 --p-value 0.10 --strand-filter 1 --map-quality 10 and 
SAMtools v0.1.16 (http://samtools.sourceforge.net). [52 - 53]  False positives were removed 
as previously described in Koboldt et al. 2012. [52]  Small insertion/deletion variants 
(indels) were called by VarScan v2.2.9 with the same parameters and false-positive filtering. 
[52] 
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Sample Exome Kit Reads Mapped Map Rate Dup Rate Total Gbp Coverage at 20x Coverage at 1x 
RFS132-5721 Nimblegen v2 122,509,234 121,017,610 98.78% 23.67% 12.25 93.76% 99.29% 
RFS132-7467 Nimblegen v2 107,049,676 105,665,194 98.71% 25.79% 10.70 91.25% 99.29% 
RFS132-7472 Nimblegen v2 95,077,414 93,874,908 98.74% 27.81% 9.51 89.08% 99.17% 
RFS132-7827 Nimblegen v2 73,681,406 72,817,044 98.83% 20.37% 7.37 80.89% 98.83% 
RFS132-7473 Agilent v2b 230,730,994 226,027,730 97.96% 20.61% 23.07 80.82% 96.51% 
RFS132-5948* Agilent v2b 218,628,518 208,132,924 95.20% 21.09% 21.86 75.70% 94.39% 
RFS132-5949 Agilent v2b 223,637,628 210,149,218 93.97% 24.15% 22.36 74.26% 94.51% 
RFS132-5463 Agilent v2b 241,894,124 226,045,728 93.45% 21.65% 24.19 76.58% 95.29% 
 
 
 
 
Table 4. Exome sequencing data. The exome kit, total number of reads (Illumina 2x100 bp protocol), mapping rate, 
duplication rate, total sequenced data, and exome target coverage at 20x and 1x are provided.  A “*” highlights the 
unaffected spouse. 
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Variant Compilation and Annotation 
  Cross-sample variant call format (VCF) files were generated for each variant type 
(SNVs and indels). Sites that failed the false-positive filter in >50% of samples in the family 
were removed as probable artifacts.  Missing genotypes were backfilled using SAMtools 
consensus calling (samtools pileup –c). [53]  Variants were annotated with information from 
the dbSNP build 137 VCF file using the vcf-annotate command of the joinx tool 
(http://gmt.genome.wustl.edu/joinx/1.6/). [33]  Known dbSNP variants in the VCF were 
updated with RefSNP (RS) number in the ID column, as well as global minor allele 
frequency (GMAF) and mutation/clinical status (PM/OMIM/LSDB) in the INFO column. 
[33]  Variants were also annotated with gene structure information using internal software 
(and Ensembl release 70) as well as the Variant Effect Predictor (VEP) v2.2 with 
parameters: --condel b --polyphen b --sift b --hgnc --canonical.  For each gene, the canonical 
VEP annotation was used whenever possible.  In the event multiple overlapping genes 
yielded different annotations, the most damaging annotation was used.  In coding regions, 
the priority order (from most damaging to least damaging) was: frameshift, nonsense, 
essential splice site, missense, nonstop, synonymous coding.  Missense variants were 
considered damaging if called as such by at least one of Polyphen (Polymorphism 
Phenotyping, http://genetics.bwh.harvard.edu/pph2/index.shtml) (“probably_damaging” or 
“possibly_damaging”), SIFT (Sorting Intolerant from Tolerant, http://sift.jcvi.org/) 
(“deleterious”), or Condel (CONsensus DELeteriousness, http://bg.upf.edu/condel/home) 
score of missense SNVs (“deleterious”). [54 - 56] 
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Whole-Genome Sequencing 
Library Preparation 
Illumina sequencing libraries were constructed with 1µg of genomic DNA according 
to the manufacturer’s protocol (Illumina Inc.) with the following modifications: 1) DNA was 
fragmented using a Covaris E220 DNA Sonicator (Covaris, Inc.) to range in size between 
100 and 400bp  2) Illumina adapter-ligated library fragments were amplified in four 50µL 
PCR reactions for 18 cycles and  3) SPRI bead cleanup was used for enzymatic purification 
throughout the library process, as well as final library size selection targeting 300-500bp 
fragments. 
Sequence Alignment and Variant Calling 
Paired-end sequencing (2x100 bp) was performed on an Illumina HiSeq2000 
instrument and processed with Illumina sequencing pipeline software version 1.3.  Reads 
were aligned to the human reference assembly (GRCh37-lite) with BWA v0.5.9 using 
parameters -t 4 -q 5. [51]  Duplicates were marked using Picard v1.46.  SNVs were called 
using VarScan v2.2.9 with parameters --min-coverage 3 --min-var-freq 0.20 -p-value 0.10 --
strand-filter 1 and SAMtools v0.1.16 with default parameters. [52 - 53]  SNVs from the 
union of these callsets were filtered to remove systematic false positives as previously 
described in Koboldt et al. 2012.  Indels were called in an identical fashion, except that 
SAMtools was not used. 
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Variant Compilation and Annotation 
Variant Compilation and Annotation was completed as described above for whole-
exome sequencing. 
Filtering of NGS Variants  
After annotation of all SNVs and indels identified by whole-exome and whole-
genome sequencing, a set of filters was applied to the list of genetic variants in order to 
remove those that could not be the cause of disease.  These filters included: located in the 
chromosome 19q disease locus; minor allele frequency (MAF) less than 1%; minor allele 
count (MAC) less than 5; segregates with disease in the family.  Variants that did not pass 
each of these filters were removed from the list of possible disease-causing variants.    
Results 
 In a collaborative effort with our peers at the Genome Institute at Washington 
University in St. Louis, MO, seven affected family members and one unaffected spouse 
from the RFS132 family underwent exome capture and next-generation sequencing on an 
Illumina platform.  Approximately 14.4 Gbp of sequence was generated per individual. 
(Table 4)  The mapping rate and duplication rate of each individual for this sequencing data 
can be found on Table 4.  On average, 98% of the 34 Mbp of targeted coding sequence was 
covered by at least one read, and approximately 89% was covered by at least 20 reads. 
Variant calling identified 211,651 SNVs and 41,171 indels in one or more of the 
individuals sequenced.  A series of filters was applied to this list of variants to remove those 
that are not the cause of disease in this family.  Mapping data discussed in chapter 4 was 
used to filter out all variants that were not located in the chromosome 19q disease locus.  
49 
 
Variants present in online genetic databases such as the 1000 Genomes Browser 
(http://browser.1000genomes.org/index.html) and the NHLBI Exome Sequencing Project 
Exome Variant Server (NHLBI GO Exome Sequencing Project (ESP): 
https://esp.gs.washington.edu/drupal/), and/or dbSNP 
(http://www.ncbi.nlm.nih.gov/projects/SNP/) with a MAF of 1% or greater were also 
removed from the list of possible disease-causing variants. [31 - 33]  Next, MAC’s were 
hand-curated from the same online genetic databases and used to remove the variants that 
have a MAC of five or greater from the list of possible disease-causing variants.  A MAC of 
5 was chosen as the cutoff to help account for the fact that rare and disease-causing alleles 
are being increasingly located in databases such as dbSNP.  I can also not completely 
exclude the possibility that some of these databases may contain genetic information from 
an RP patient.  The final filter involved eliminating the variants that did not segregate with 
disease among the family members sequenced.  One important caveat to note about this final 
filter is that it was only applied to variants that were not seen in each affected individual 
AND reached a read depth of 20x in every individual for the bp position being considered.  
This caveat also extended to variants that were present in ONLY the unaffected spouse.  The 
caveat was applied to ensure that low coverage at any particular position did not prevent us 
from seeing the rare allele in at least one individual and, therefore, unnecessarily eliminating 
a potential disease-causing mutation.  Application of each of these filters narrowed the list of 
possible disease-causing variants identified by whole-exome sequencing down to 163 SNVs 
and 82 indels. 
Two affected members of the RFS132 family underwent whole-genome sequencing 
on an Illumina platform at Washington University’s Genome Institute.  These two 
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individuals, RFS132-5721 and RFS132-5463, were chosen for sequencing based on the 
availability of enough high quality DNA and appropriately consented individuals.  For 
sample RFS132-5721, 1.47 billion paired-end reads were generated.  Of the total paired-end 
reads generated, 94.93% were mapped to the reference sequence and 4.18% were marked as 
duplicates, yielding 44.49x average haploid coverage.  For sample RFS132-5463, 1.07 
billion paired-end reads were generated.  However, only 19.32x haploid coverage was 
achieved due to a low mapping rate (66.7%) and elevated duplication rate (7.03%), likely 
the result of low quality DNA.  The same set of filters was applied to all the variants 
identified by whole-genome sequencing.  Additionally, variants that were already seen from 
whole-exome sequencing were removed to avoid repeat variants as the two lists would 
eventually be combined.  Removal of all genetic variants already seen in whole-exome 
sequencing and variants not present in the chromosome 19q disease locus narrowed the list 
of variants to 260 SNVs and 185 indels.  Application of the final three filters further 
narrowed the list of whole-genome sequencing variants to 106 SNVs and 164 indels. 
Discussion 
Multiple NGS strategies were used to identify the full of array of genetic variation 
located in RFS132’s chromosome 19q disease locus.  Whole-exome sequencing was used to 
focus on identification of genetic variants in the coding and splice regions of the genome as 
this is where the majority of currently known RP mutations lie.  Whole-genome sequencing 
was subsequently employed to identify any genetic variants located in the non-coding 
regions of the genome.  Whole-genome sequencing was also used to avoid artifacts 
introduced by exome capture and add sequencing read depth to the regions assayed by 
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whole-exome sequencing in an effort to identify any variants missed by whole-exome 
sequencing. 
These two NGS methods successfully identified thousands of coding and non-coding 
variants.  The disease-causing mutation for RFS132’s adRP should be present in the mapped 
disease locus and present in the heterozygous state of each affected family member.  Since 
RP is a rare disease, the disease-causing mutation should also be a rare variant that is not 
present in unaffected controls.  Therefore, a set of filters was applied to this large list of 
genetic variants to remove variants that were: 1) not located within the mapped disease locus 
2) had a MAF of 1% or greater 3) had a hand-curated MAC of 5 or greater and 4) not 
segregating with disease in the sequenced family members.  Variants that did not pass these 
filters should not be the cause of disease in RFS132.   
After application of the filters, 269 SNVs and 264 indels remained on our list of 
possible disease-causing variants.  These are rare variants located in the disease locus and 
segregating with disease in the family members sequenced.  With so many variants still 
remaining, additional genetic and bioinformatics analyses are necessary to determine if one 
(or more) of these variants is RFS132’s disease-causing mutation.  Chapter 7 will discuss the 
steps taken to evaluate the potential pathogenicity of the remaining variants. 
 
 
 
 
52 
 
Chapter 7: Genetic and Bioinformatic Follow-up of Next-Generation 
Sequencing Variants 
Introduction 
NGS has seen a continual stream of improvements and growth in applicable uses.  
The ability to quickly screen a patient’s entire genome provides great opportunities for 
scientists in the identification of novel disease-causing genes.  The cost of NGS also makes 
these methods available to a large number of scientists. 
However, it is the elucidation of the specific disease-causing mutation from among 
the data produced by NGS that is slowing down disease-gene identification.  Many scientists 
struggle under the weight of the large amount of data produced by NGS.  The pathogenic 
allele must be identified from among the numerous non-pathogenic polymorphisms and 
sequencing errors.  The complex nature of the transcriptome increases the difficulty of 
delineating biological causation.  Rare genetic diseases can only provide us with a small 
number of patients to study.  Genetically heterogeneous diseases introduce the possibility of 
the remaining disease-causing mutations being family-specific.  This lowers the opportunity 
of confirming pathogenicity in additional families with the same disease. 
There is currently no set method for overcoming these complications and identifying 
the disease-causing mutation from among the large amount of data produced by NGS.  This 
chapter discusses the additional genetic and bioinformatic steps I have taken to evaluate the 
pathogenic potential of the remaining 269 SNVs and 246 indels identified by NGS.  The 
variants were verified in a subset of the RFS132 family using Sanger sequencing, still 
considered the gold standard of sequencing, in order to remove those that were false 
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positives, paralogous variants, or not segregating with disease.  After verification, the 
remaining variants were sequenced in all 28 members of the family to test, once again, for 
appropriate segregation with disease.  The final set of remaining rare variants were then 
evaluated, to varying degrees, for their presence in additional adRP families, their location 
in a gene expressed in the retina, the occurrence of different mutations in the same gene for 
additional adRP families, and the effect they induce on the gene’s protein. 
Methods 
Sanger Sequencing 
AmpliTaq Gold® 360 Master Mix (Life Technologies) and M13-tailed primers 
designed in Primer3 were used to amplify genomic DNA in a 12.5 µL reaction volume for 
35 cycles. [25 - 26]  The resulting PCR products were treated with ExoSAP-IT® 
(Affymetrix).  Purified PCR products were sequenced bidirectionally with M13 primers and 
BigDye v1.1 (Life Technologies).  Sequence reactions were purified with BigDye 
Xterminator® purification kit and run on a 3500 Genetic Analyzer (Life Technologies).  
Sequence analysis was then performed with SeqScape® v3.0 (Life Technologies). 
Results 
Verification of NGS Variants  
The remaining 269 SNVs and 246 indels were Sanger sequenced in two affected 
individuals and one unaffected spouse in the RFS132 family and analyzed with Life 
Technologies SeqScape® software v3.0.  PCR primers were designed to include at least 50 
additional bps on either side of the variant being sequenced in order to improve the quality 
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of the sequence seen at the variant location.  Validation of these variants was necessary to 
remove those that were false positives, paralogous variants, or not segregating with disease 
in the family members sequenced.  Verification efforts removed all but 64 SNVs and 3 
indels from the list of possible disease-causing variants.  There were also 16 additional 
variants that I was unable to verify.  My inability to use Sanger sequencing to verify each of 
these 16 variants was due to the extremely repetitive nature of where these variants were 
located (Figure 9). 
Analysis of NGS Variants in the Entire Family 
 After verifying that the remaining 64 SNVs and 3 indels were true genomic variants, 
they were Sanger sequenced in all 28 members of the RFS132 family (Figure 4).  This was 
used for verification that each variant segregated with disease in the family.  Although 
previously discussed analyses showed that each of these variants segregated with disease in 
the family members sequenced, verification of these results in the entire family provides 
important additional information.  The unaffected spouses offer additional ethnically 
matched control samples.  Also, some family members had varying sizes of the affected 
haplotype (Figure 8).  These rare variants provide an additional opportunity to redefine the 
boundaries of the disease locus.  Four variants failed to segregate with disease in RFS132-
5722.  This affected family member also has the recombination that defines the telomeric 
boundary of the disease locus.  Therefore, these four variants were found to be non-
pathogenic and used to redefine and narrow the telomeric boundary of the disease locus 
(Figure 10).  A C > T SNV in the intron of KLK15 at 51,334,646 bps now sets the telomeric 
boundary of the disease locus and narrows the disease locus by 215,386 bps and 13 genes.  
The remaining 63 variants segregated with disease in all available members of the  
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A) 
B) 
Figure 9. Repetitive regions of the disease locus. A and B 
show electropherograms of repetitive regions where NGS 
indicated variants were located.  The inability to confidently 
sequence all the way through these repetitive regions 
prevented the putative NGS variants located here from 
being verified. 
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Figure 10. Use of NGS variants to redefine the disease locus boundaries.  
The identification of 4 NGS variants that did not segregate with disease in 
RFS132-5722 allowed the disease locus to be narrowed by 215, 386 bps and 
13 genes. 
215,386 bps 
and 
13 genes 
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RFS132 family. 
Analysis of Rare NGS Variants Segregating with Disease in the Family 
 The final 63 variants are rare SNVs or indels identified by NGS that have been 
verified as real genomic variants and shown to segregate appropriately with disease in the 
entire RFS132 family.  These variants include a variety of variant classes spread throughout 
the disease locus (Table 5).  Only one of these variants, a synonymous SNV in SYMPK, is 
located in the protein-coding region of a gene.  Therefore, priority was given to this variant 
for additional follow-up analysis. 
 Symplekin (SYMPK) encodes a nuclear protein involved in the regulation of 
polyadenylation and promotion of gene expression. [57]  SYMPK is believed to serve as a 
scaffold for recruiting regulatory factors to the polyadenylation complex. [57] SYMPK also 
participates in 3' processing of replication-dependent histone mRNAs, which do not undergo 
polyadenylation. [57]  The NGS variant identified in SYMPK is a synonymous C > T SNV 
located at 46,334,722 bp (Figure 11).  This synonymous SNV changes the codon of the 
Leucine located at the 506th amino acid of the SYMPK protein.  Previous analysis in chapter 
6 shows this variant is not present in any online genetic databases such as the 1000 Genomes 
Browser and dbSNP.  This variant was then Sanger sequenced in an additional 96 ethnically 
matched controls to search for the presence of this variant in individuals that do not have 
RP.  The SYMPK SNV was not found in any of the individuals sequenced.  Next, the entire 
SYMPK gene was Sanger sequenced in 83 individuals from families that have been 
diagnosed with adRP.  These families are part of a well-characterized and previously 
described adRP cohort in which all known causes of adRP have been eliminated. [15]  This 
step was completed to search for the presence of this variant or any other variant in  
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Variant Class Number of SNVs Number of Indels 
Synonymous 1 0 
5' UTR 2 0 
3' UTR 7 0 
Intronic 43 2 
Intergenic 7 1 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5. Classification of NGS variants 
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Figure 11. Synonymous SYMPK SNV 
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additional families with adRP.   Identification of SYMPK mutations in additional families 
would have greatly strengthened the pathogenic potential of this variant.  However, I was 
unable to find this variant or any others in the SYMPK gene in the 83 families sequenced. 
 This novel SYMPK SNV was then analyzed in silico to help determine the likelihood 
of it being a pathogenic mutation.  Retinal transcriptome data shows that each exon of 
SYMPK is well-expressed in the retina. [44]  This transcriptome data also shows that there 
are no retinal-specific exons or splice junctions located in this gene. [44]  Alternate 
transcripts of SYMPK place this SNV in the terminal exon, which could be significant if 
there is any alternative splicing or alternative 3' polyadenylation taking place in this gene in 
RFS132.  The SNV occurs at a well-conserved bp position in the gene (Table 6).  SpliceAid 
Anlysis (http://www.introni.it/splicing.html) indicates the SYMPK SNV destroys an 
hnRNPA1 (heterogeneous nuclear ribonucleoprotein A1) binding site. [58]  Many of these 
hnRNPs are implicated in splicing as they bind to pre-mRNA before assembly of the 
splicesome. [59]  More specifically, studies indicate hnRNPA1 is involved in U2AF 
mediated 3' splice site recognition. [59]  All of this information together suggests the 
possibility of alternative splicing taking place in individuals with this variant.  Additional in 
vitro studies will be necessary to confidently determine the effect the SYMPK SNV has on 
the SYMPK transcript in the RFS132 family.  However, more studies might be premature 
with 62 additional variants segregating with disease in this family. 
 The 63 rare NGS variants segregating with disease in this family can be found in 
Table 7.  Each of these variants received varying degrees of the same follow-up analyses 
completed on the SYMPK SNV.  Multiple biological properties were taken into account  
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Organism DNA Sequence 
Human GTGGGTTCCCTGAGCTCCATGTC 
Chimp GTGGGTTCCCTGAGCTCCATGTC 
Gorilla GTGGGTTCCCTGAGCTCCATGTC 
Orangutan GTGGGTTCCCTGAGCTCCATGTC 
Baboon GTGGGTTCCCTGAGCTCCATGTC 
Tree shrew CTGGGCTCCCTGAGCTCCATGTC 
Mouse GTAGGCTCTCAGAGCACCATGTC 
Guinea pig GTGGGCTCTCTGAGCTCCATGTC 
Squirrel GTGGGCTCTCTGAGCTCCATGTC 
Rabbit GTGGGGTCCCTGAGCGCCATGTC 
Dolphin GTGGGCTCCCTGAGCTCCATGTC 
Cow GTGGGCTCCCTGAGCTCCATGTC 
Horse GTGGGCTCCCTGAGCTCCATGTC 
Cat GTGGGCTCCCTGAGCTCCATGTC 
Dog GTGGGCTCCCTGAGTTCCATGTC 
 
 
 
 
 
Table 6. Conservation of the synonymous SYMPK variant 
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BP 
Position REF ALT dbSNP ID 
Variant 
Class Variant Gene Comments 
44,112,426 
ACTGGC
ACCCAG
TAGATT
CC 
A rs67507730 intronic SRRM5 Overlaps with an intron of ZNF428 on the antisense  Strand 
44,157,037 A G rs4251908 intronic PLAUR 
 
44,676,922 A G . intronic ZNF226 
 
44,865,824 T A rs182300049 intronic ZFP112 AFR MAC in 1000 Genomes: 4 
44,901,201 A G rs113715157 intronic ZNF285 
 
45,116,478 A T rs185907451 intronic CEACAM22P Low retinal expression; AFR MAC in 1000 Genomes: 3 
45,130,502 G C rs184945473 intronic IGSF23 Low retinal expression; AFR MAC in 1000 Genomes: 4 
45,162,594 G A . intronic PVR 
 
45,251,743 C T . intronic BCL3 
 
45,324,374 T A . 3' UTR BCAM 
 
45,392,527 A G . intronic ENSG00000267282  
45,563,561 C T . intronic CLASRP 
 
46,005,597 A C . 3' UTR PPM1N 
 
46,011,052 C G . intronic VASP 
 
46,020,678 G T . intronic VASP 
 
46,024,787 C T rs192868401 intronic VASP AFR MAC in 1000 Genomes: 1 
46,024,912 C T . intronic VASP 
 
46,031,983 C A rs182553559 3' UTR OPA3 AFR MAC in 1000 Genomes: 3 
46,182,003 G A rs184478662 intronic GIPR AFR MAC in 1000 Genomes: 1 
46,270,818 G A . intronic SIX5 
 
Table 7. NGS variants segregating with disease in RFS132 
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46,331,268 G A . intronic SYMPK 
 
46,334,722 C T . synonmous SYMPK Splicing Aid Analysis: eliminates an hnRNP A1 binding 
site 
46,341,285 T C . intronic SYMPK 
 
46,351,421 G A . intronic SYMPK 
 
46,545,943 A G rs148383368 intergenic . AFR MAC in 1000 Genomes: 2 
46,582,514 T C . intergenic . 
 
46,582,726 C T . intergenic . 
 
46,623,858 A G . intronic IGFL3 Low retinal expression 
46,626,912 T G rs143430345 intronic IGFL3 Low retinal expression; AFR MAC in 1000 Genomes: 4 
47,192,657 G A . intronic PRKD2 
 
47,216,922 A G rs115121958 intronic PRKD2 AFR MAC in 1000 Genomes: 4 
47,225,866 C T . intronic STRN4 
 
47,227,890 G A . intronic STRN4 
 
47,234,613 C T rs115655565 intronic STRN4 
 
47,235,891 C T rs116745685 intronic STRN4 AFR MAC in 1000 Genomes: 4 
47,241,023 C T rs116286078 intronic STRN4 AFR MAC in 1000 Genomes: 4 
47,546,304 C T . intronic NPAS1 
 
47,603,149 T C rs186045365 intronic ZC3H4 AFR MAC in 1000 Genomes: 2 
47,634,429 G A . intronic SAE1 
 
47,998,467 T A . intronic NAPA 
 
48,052,265 G A rs10417667 intronic ZNF541 Low retinal expression 
48,205,788 C T . 3' UTR GLTSCR1 
 
48,245,113 A T . 3' UTR EHD2 
 
48,248,317 C T rs183699501 intergenic . 
 
48,848,708 T C rs111791335 intronic TMEM143 
 
48,949,049 C G . 5' UTR GRWD1 
ENCODE:Histone:H2AZ,Histone:H2BK120ac,Histone:H
2BK20ac, 
Histone:H2BK5ac,Histone:H3K18ac,Histone:H3K27ac, 
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Histone:H3K27me3,Histone:H3K36ac,Histone:H3K4ac, 
Histone:H3K4me2,Histone:H3K4me3,Histone:H3K56ac, 
Histone:H3K9ac,Histone:H4K5ac,Histone:H4K8ac, 
Histone:H4K91ac,OpenChromatin:DNase1, 
OpenChromatin:FAIRE,Polymerase:PolII, 
TranscriptionFactor:CBP,TranscriptionFactor:CTCF, 
TranscriptionFactor:Cmyc,TranscriptionFactor:E2F1, 
TranscriptionFactor:E2F4,TranscriptionFactor:ELF1, 
TranscriptionFactor:ETS1,TranscriptionFactor:Gabp, 
TranscriptionFactor:HDAC1,TranscriptionFactor:HEY1, 
TranscriptionFactor:Max,TranscriptionFactor:SIX5, 
TranscriptionFactor:Sin3Ak20,TranscriptionFactor:TAF7, 
TranscriptionFactor:Yy1,TranscriptionFactor:ZBTB33 
49,015,119 G A . intronic LMTK3 
 
49,533,770 C T . intergenic . 
 
49,593,153 C T rs190028492 intronic SNRNP70 AFR MAC in 1000 Genomes: 3 
50,097,088 C T . intronic PRR12 
 
50,270,285 C G . 5' UTR AP2A1 
ENCODE:Histone:H3K27ac,Histone:H3K27me3, 
Histone:H3K4me2,Histone:H3K4me3, 
Histone:H3K9ac,OpenChromatin:DNase1, 
Polymerase:PolII,TranscriptionFactor:Cfos, 
TranscriptionFactor:E2F4, 
TranscriptionFactor:ELF1, 
TranscriptionFactor:Gabp, 
TranscriptionFactor:Pbx3, 
TranscriptionFactor:SP1, 
TranscriptionFactor:SP2, 
TranscriptionFactor:Sin3Ak20 
50,354,289 G A . intronic PTOV1 
 
50,367,424 G A . intronic PNKP 
 
50,655,625 T C . intergenic . 
 
50,657,268 G C . intronic IZUMO2 Low retinal expression 
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50,818,774 G A . 3' UTR KCNC3 
 
50,819,228 G C . 3' UTR KCNC3 
 
50,927,298 G A . intronic SPIB Low retinal expression 
50,969,387 C T . intronic MYBPC2 
 
51,114,887 T TTTTA . intergenic .  
51,124,773 C T . intergenic . 
 
51,168,591 T TG . intronic SHANK1 
 
51,206,017 G C . intronic SHANK1 
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when evaluating the pathogenic potential of these variants and the need for additional 
analysis.  Several of these variants have MAC’s that are above zero and below five.  While 
these variants are not novel, they are below the previously discussed MAC filter of five or 
greater (Chapter 6).  Since the online genetic databases that we used to evaluate the 
frequency of these variants are more biased towards whole-exome sequencing data, it is 
possible these variants occur in the population at a frequency greater than databases 
currently suggest.  Reaching out to collaborators with access to large whole-genome 
sequencing studies can help determine how polymorphic these variants truly are. 
Discussion 
 NGS has provided unprecedented ability to detect genetic variants throughout an 
individual’s genome.  However, the ability to detect more variants is increasing the 
difficulty of determining which of those variants is pathogenic.  In this chapter, the 
pathogenic potential of the 269 SNVs and 246 indels that passed filtering in chapter 6 was 
evaluated. 
 Sanger sequencing was used to verify whether any of these variants were false 
positives, paralogous variants, or failing to segregate with disease.  This narrowed the list of 
candidate variants down to 67.  Sanger sequencing is capable of producing much longer 
sequencing read lengths than those typically used in NGS platforms.  These longer reads 
provide greater specificity to regions of the genome and enabled detection of false positives 
and paralogous variants.  Additional segregation analyses in the remaining RFS132 family 
members identified four SNVs that failed to segregate with disease in RFS132-5722.  This 
information was used to redefine the boundaries of our disease locus and narrow the critical 
region to 7.5 Mb and 343 genes. 
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 A total of 63 rare variants segregating with disease were identified by NGS in the 
RFS132 family.  These variants are spread throughout the disease locus and are in a variety 
of variant classes.  Genetic and bioinformatic analyses were completed to evaluate these 
variants’ potential to be disease-causing.  Priority was place on the SYMPK variant because 
it is the only one located in a protein-coding region.  Additional in vitro studies are 
necessary to confidently determine the likelihood of any of these variants causing disease in 
RFS132.  However, with 63 candidate variants remaining, this list is likely too extensive for 
in vitro studies to be completed on each one. 
 Data sharing efforts have been initiated with scientists studying RP across the 
country.  RP is a rare genetic disease, and the remaining adRP disease-causing variants may 
be extremely rare and/or private variants.  Therefore, we have asked these researchers to 
search for the presence of any of the remaining 63 NGS variants (or variants within the same 
genes) in adRP families available to them in their lab in addition to our screening of the 
families available in the Daiger laboratory.  Identification of one of these NGS variants 
would greatly increase its priority for follow-up analysis.   
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Chapter 8: Conclusions and Future Directions 
Advancement of RP Research 
RP research has seen great success over the past two decades.  Sixty-three genes 
have been shown to cause RP and over 3,100 mutations have been identified among these 
genes. [5, 7]  The tools used for disease-gene discovery have also improved and become 
more powerful, notably the advent of NGS.  With the continual identification of new 
disease-causing genes and advances in genetic technologies, many hope and predict that it 
will be possible to detect the genetic cause of disease in 95% of RP patients within the next 
five years. [5] 
 Continuing towards the goal of molecular diagnosis in 100% of known RP patients is 
extremely important because accurate molecular diagnosis is an essential step in the 
development of treatments for these RP patients.  Identification of the remaining disease-
causing genes will help improve our understanding of the visual process by identifying any 
additional biological pathways involved in RP.  This is specific information that can be used 
in the management and treatment of the vision loss seen in RP patients.  For example, 
Bowne et al. 2011 identified the first dominant-acting RP mutation in RPE65, a gene in 
which recessive RP and recessive LCA mutations had already been identified. [14]  AAV-
mediated gene-replacement therapy had already successfully treated LCA patients with 
recessive RPE65 mutations. [14]  Therefore, similar treatment methodology is likely to be 
successful in treating RP patients with dominant RPE65 mutations. [14]  It is an exciting 
time in research when identification of a patient’s mutation can quickly and directly lead to 
treatment of their life-altering disease. 
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Summary of Results 
Despite the already large number of genes associated with RP, our search for novel 
disease-causing genes is not complete.  Disease-causing mutations have not been identified 
in 30-35% of patients with adRP. [5]  The goal of my research is to increase the number of 
known genes associated with adRP.  RP is extremely genetically heterogeneous, and it is 
unknown how often the remaining disease-causing mutations will appear in the RP 
population.  Therefore, I have taken a family-by-family approach in identifying novel adRP 
genes and have used a multitude of advanced genetic techniques to search for the disease-
causing gene and mutation in an African American family referred to as RFS132.  This 
systematic and thorough process is also quite circular (Figure 3).  Each new piece of 
information involves a re-evaluation of what we know at all of the previous steps and feeds 
into how we approach the following steps. 
RFS132 was enrolled in this study after the family’s proband received a clinical 
diagnosis of adRP for his vision loss. Informed consent and DNA samples were obtained 
from a total of 28 members of this muti-generational African American family.  Seven 
family members received comprehensive visual function exams that highlighted the varying 
degrees of severity in their symptoms.  The visual exams also displayed their poor visual 
acuity, elevated dark-adapted thresholds, and significant loss of rod and cone 
photoreceptors.  Each of these symptoms is consistent with a diagnosis of RP, and they will 
provide possible guidance for identifying the disease-causing mutation once candidate 
variants have been identified.   
Since a total of 23 genes are already known to cause adRP, it was imperative to 
evaluate and eliminate all known causes of adRP in this family.  Sanger sequencing was 
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used to screen the exons and exon/intron junctions of the known adRP genes.  MLPA was 
used to screen for CNVs and genomic rearrangements that might be missed by conventional 
sequencing methods in a subset of the known adRP genes.  Targeted capture NGS was used 
to screen the exons and splicing regions 48 RP genes and 115 additional retinal disease 
genes.  Each of these methods was unable to identify a potential disease-causing mutation in 
the known causes of adRP.  Additionally, all NGS variants identified by whole-exome and 
whole-genome sequencing in known adRP genes, including intronic and regulatory variants, 
were evaluated and eliminated as the possible cause of disease. 
Whole-genome linkage analysis followed by fine-point haplotype analysis using 
STR markers and rare NGS variants mapped RFS132’s disease locus to a 7.5 mega-base 
region on chromosome 19q.  A total of 343 genes are located in this disease locus of which 
254 are expressed in the retina.  CNV analysis, using data generated from an Affymetrix 6.0 
SNP array, did not identify any copy number variants. 
Five candidate genes, CRX, OPA3, CABP5, SNRNP70, and SNRPD2, located 
within this disease locus were chosen as likely candidates to cause disease based on their 
biological relevance to RP.  Sanger sequencing was used to screen these genes for possible 
disease-causing mutations.   
Whole-exome sequencing and whole-genome sequencing were used to identify all of 
the genetic variants located in the chromosome 19q disease locus.  These NGS strategies 
identified 63 rare variants located throughout the disease locus that segregate with disease in 
the entire family.  Additional genetic and bioinformatic analyses were completed to evaluate 
these variants’ potential to be disease-causing.  Each of these 63 variants is still a candidate 
for RFS132’s disease-causing mutation.  Priority is placed on the synonymous SYMPK SNV 
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as it is the only variant located in the coding region of a gene.  Even though it is 
synonymous, in silico analysis indicates this SNV destroys an hnRNP A1 binding site. 
Future Directions 
Despite significant effort and the use of multiple genetic technologies, I have not yet 
been able to single-out RFS132’s disease-causing mutation.  However, the wealth of 
detailed genetic information produced in this study should be used to continue the search for 
this family’s disease-causing gene.  Identifying the genetic cause of RFS132’s adRP will 
provide the family with information that can be used in a more accurate and thorough 
diagnosis and prognosis of their disease.  This information will also be beneficial to any 
other families identified with mutations in the same gene. 
The first step in moving forward is outlining each of the reasons that may have 
prevented the confident identification of RFS132’s disease-causing mutation. These reasons 
are as follows: 1) The disease-causing mutation is not on chromosome 19. 2) We dismissed 
the disease-causing mutation as non-pathogenic during the course of this study. 3) The 
disease-causing mutation is one of the variants segregating with disease. 4) The disease-
causing mutation is in a region that is poorly covered by NGS, and the rare, disease-causing 
allele was never seen. 5) The disease-causing mutation is not detectable by current 
sequencing technologies.  I feel the first two of these reasons are the least likely.  Whole-
genome linkage analysis identified three different chromosomal regions with a positive LOD 
score.  These results were confirmed and refined with an additional genetic technique, fine-
point haplotype analysis.  Generating haplotypes for each of these chromosomal regions 
showed only one chromosomal region with a haplotype that tracked with disease.  I also feel 
it is unlikely that the pathogenic variant was dismissed as non-pathogenic during the course 
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of this study.  Every attempt was made to be conservative with the filters and elimination 
criteria applied to my data. 
The third possible scenario is that one of the 63 rare variants identified by NGS is the 
cause of disease.  I am not alone in the struggle to pinpoint the disease-causing mutation 
from among the large amount of genetic data that I have laboriously produced.  Multiple 
reviews cite identification of the pathogenic allele as the ‘rate-limiting’ step in the analysis 
of NGS data. [16 – 18]  While many studies proceed toward functional validation after a list 
of candidate variants is identified, I feel there are still too many possible candidates for 
functional validation and would be an unwise use of time and resources.  Priority should be 
placed on narrowing the disease locus and searching for overlapping candidate variants 
among additional adRP families.  I detail each of these suggestions later on. 
The final possibilities to consider are that the disease-causing mutation is in a region 
poorly covered by NGS or the disease-causing mutation is not detectable by current 
sequencing technologies.  Both of these would mean that the disease-causing mutation has 
not yet been seen.  The 20x read depth coverage and mapping rates found in Table 4 and in 
the results section of chapter 6 indicates that both of these are viable options.  
Computational methods have a difficult time confidently mapping the relatively short NGS 
reads to repetitive regions of the genome.  NGS and conventional sequencing methods also 
have a difficult time detecting certain types of mutations, such as large deletions and 
rearrangements.  Despite our use of CNV analysis, MLPA, and NGS strategies, it is possible 
we have missed some of these large deletions or genomic rearrangements.  Tucker et al’s 
2011 identification of a homozygous Alu insertion in a MAK (male germ cell-associated 
kinase) exon as the cause of RP in an isolated individual is a prime example of why these 
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mutation types should not be over-looked.  As sequencing technologies continue to improve, 
our ability to detect these mutation types will increase. 
I feel one of the most valuable sources of information for the future of this study lies 
within the family members’ genetic and clinical information.  It has already been mentioned 
that working with the family is an ongoing process.  It is extremely important to encourage 
and assist more members of the family in getting thorough visual function exams.  RP’s 
varying age of onset also makes it important to update the exams of those that have already 
been seen before.  Figure 8 shows several unaffected, at-risk family members have smaller 
pieces of the current disease locus.  If any of these individuals’ disease status is updated 
from at-risk to affected, we would be able to narrow the genomic region in which we are 
searching for the disease-causing gene.  There are also additional younger members of this 
family that can still be enrolled in this study.  Each of those with an affected parent has a 
50% chance of developing RP.  Each of these also has a possibility of having a 
recombination within the current disease locus that can be used to redefine the boundaries 
and narrow the disease locus.  This will provide valuable focus to the search for the genetic 
cause of disease as there are a large number of candidate genes and variants still located 
within the current disease locus. 
In the current age of genetic research, it is important for us to increase our venues for 
data sharing.  Sharing and comparing the results seen in multiple genetic laboratories can 
help advance our research.  Other labs might have candidate variants that overlap with one 
or more from the list I am struggling to narrow down.  Seeing a variant shared among more 
than one adRP family would provide the evidence necessary to strengthen the pathogenic 
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potential of a candidate variant.  Data sharing with multiple RP researchers around the 
country has already been initiated for this family. 
In conclusion, I have identified a novel adRP locus on chromosome 19q that is 7.5 
Mb in size and contains the disease-causing gene for the RFS132 family.  I have also 
identified 63 rare variants located throughout the disease locus that segregate with disease in 
this family.  Each of these variants remains a potential candidate for the disease-causing 
mutation.  Use of the valuable genetic information that I have produced in this study will 
allow for the identification of this family’s disease-causing gene and mutation in the near 
future. 
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Genes in Capture Panel 
A6NGG8 COL11A1 MYO7A RDH5 
ABCA4 COL2A1 NDP RGR 
ABCC6 COL9A1 NPHP1 RGS9 
ADAM9 CRB1 NPHP3 RGS9BP 
AHI1 CRX NPHP4 RHO 
AIPL1 CYP4V2 NR2E3 RIMS1 
ALMS1 DFNB31 NRL RLBP1 
ARL6 DMD NYX ROM1 
ARMS2 EFEMP1 OAT RP1 
ATXN7 ELOVL4 OFD1 RP2 
BBS1 ERCC6 OPA1 RP9 
BBS10 EYS OPA3 RPE65 
BBS12 FBLN5 OPN1LW RPGR 
BBS2 FSCN2 OPN1MW RPGRIP1 
BBS4 FZD4 OPN1SW RPGRIP1L 
BBS5 GNAT1 OTX2 RS1 
BBS7 GNAT2 PANK2 SAG 
BBS9 GPR98 PAX2 SEMA4A 
BEST1 GRK1 PCDH15 SNRNP200 
C2 GRM6 PDE6A SPATA7 
C3 GUCA1A PDE6B TEAD1 
CA4 GUCA1B PDE6C TIMM8A 
CABP4 GUCY2D PDZD7 TIMP3 
CACNA1F HMCN1 PEX1 TLR3 
CACNA2D4 HTRA1 PEX2 TLR4 
CC2D2A IDH3B PEX7 TMEM126A 
CDH23 IMPDH1 PGK1 TOPORS 
CDH3 INPP5E PHYH TREX1 
CDHR1 INVS PITPNM3 TRIM32 
CEP290 IQCB1 PRCD TRPM1 
CERKL JAG1 PROM1 TSPAN12 
CFB KCNJ13 PRPF3 TTC8 
CFH KCNV2 PRPF31 TTPA 
CHM KLHL7 PRPF8 TULP1 
CLN3 LCA5 PRPH2 UNC119 
CLRN1 LRAT RAX2 USH1C 
CNGA1 LRP5 RB1 USH1G 
CNGA3 MERTK RBP3 USH2A 
CNGB1 MFRP RBP4 VCAN 
CNGB3 MKKS RD3 WFS1 
CNNM4 MTTP RDH12  
Appendix A. Retinal Disease Genes Included in Capture Panel for Targeted 
Capture NGS.  These are the 163 reported retinal disease genes that had been 
reported in RetNet at the time of capture panel design. [7, 22] 
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Marker Forward primer Reverse primer Size Location 
D19S220 ATGTTCAGAAAGGCCATGTCATTTG TCCCTAACGGATACACAGCAACAC 265-283 bps 38,431,551 bp 
D19S420 CTGGGGCAGGAGCACT GCTTACCAAACCTAAAGGATGTC 251-267 bps 43,808,760 bp 
D19S900 CCTAATAATCAGTCACTGTCTGG TTACATGATGCTGGGAACAC 141-177 bps 44,167,258 bp 
D19S538 CACAACACTGTTCATTTGTC TTTCAGTAGAATTTCAGGCC 143-181 bps 44,405,515 bp 
D19S903 ACCGCACTCCACCCTG TCCTCCTGTGAGATCCTCG 132-166 bps 45,045,901 bp 
D19S918 AAAGGCTTGATTACCCCCGA GATTACAGGCGTGAGCACCG 140-182 bps 45,514,778 bp 
D19S908 GTAAGCCAAGATCACTCCCC GCCAGGCACTGTTCTGAATA 200-232 bps 45,870,527 bp 
D19S219 GTGAGCCAAGATTGTGCC GACTATTTCTGAGACAGATTCCCA 160-190 bps 45,993,577 bp 
DM CTTCCCAGGCCTGCAGTTTGCCCATC GAACGGGGCTCGAAGGGTCCTTGTAGC 72-129 bps 46,273,386 bp 
D19S412 TGAGCGACAGAATGAGACT ACATCTTACTGAATGCTTGC 89-113 bps 47,010,944 bp 
D19S606 AGGGCTGGGACCTCAC CCAACACACTGTCTGCCTT 172-190 bps 47,973,563 bp 
D19S902 CCATCCTAATGAGGGCAA GCACCAGTGACTGCCTGT 199-217 bps 48,332,028 bp 
D19S904 ACAAGAATTGCTTGAACCTGG GCTCCATTTCGGAGATGTTA 210-224 bps 50,776,794 bp 
D19S907 GTGTCCAATCAACAGACCA CTGCACTCCAGCAGAAAT 213-223 bps 51,061,251 bp 
D19S553 CATGCCTCTAGTCCCAGCT GACAAATGCCAGAAAGCCTG 362-479 bps 51,549,504 bp 
 
 
Appendix B. Chromosome 19 STR marker primer sequences.  Only primer sequences for STR markers run on chromosome 19 
were included because all other chromosomal regions were effectively ruled-out as potential regions linked to disease in this 
family. The information about these primers contained in this appendix will be useful in continuing the search for this family's 
disease-causing gene as new family members enrolled in the study will have to be genotyped with these markers to determine if 
they have the affected haplotype. 
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